DDInter1853 DDInter782
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of [vitamin A] (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles [A257474,A258185] and activates nuclear receptors to regulate epithelial cell growth and differentiation.[A257474,A257629,A257609] Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.[L45389,L34869,L45384]
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Tretinoin {u} (Compound) treats {v} (Disease) peripheral nervous system neoplasm
Tretinoin {u} (Compound) binds {v} (Gene) CYP1A1
Tretinoin {u} (Compound) upregulates {v} (Gene) DHRS3
Tretinoin {u} (Compound) is included by {v} (Pharmacologic Class) Retinoids
Tretinoin {u} (Compound) downregulates {v} (Gene) ATP6V1D
Tretinoin {u} (Compound) causes {v} (Side Effect) Agranulocytosis
Tretinoin (Compound) resembles Isotretinoin (Compound)
Tretinoin (Compound) treats peripheral nervous system neoplasm (Disease)
Tretinoin (Compound) binds CYP1A1 (Gene)
Tretinoin (Compound) upregulates DHRS3 (Gene)
Tretinoin (Compound) is included by Retinoids (Pharmacologic Class)
Tretinoin (Compound) downregulates ATP6V1D (Gene)
Tretinoin (Compound) causes Agranulocytosis (Side Effect)